Concepedia

Author

Oleg Gluz

Ludwig-Maximilians-Universität MünchenORCID

Also Known As

Gluz, O., Nadia Harbeck, Nina Radosevic-Robin, O Gluz, O. Gluz, OLEG GLUZ, Oleg Gluz, R. Kates

416

Publications

6.6K

Citations

37

H-Index

64

Concepts

All Affiliations

Ludwig-Maximilians-Universität MünchenMedizinische Hochschule HannoverDeutsches Archäologisches Institut, ZentraleKliniken Essen-MitteCharité - Universitätsmedizin Berlin
OG

About

Oleg Gluz is an author at Ludwig-Maximilians-Universität München specializing in medicine, breast cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

18

36

1.5K

2

Health Sciences

10

10

286

3

Public Health

3

3

39

4

Engineering

1

1

21

5

Nursing

1

1

37

Oleg Gluz

×

77

Publications

3.6K

Citations

31

H-Index

YearCitations

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz, Ulrike Nitz, Matthias Christgen,

Journal of Clinical Oncology

2016

357

Trastuzumab emtansine (T-DM1) renders HER2 <sup>+</sup> breast cancer highly susceptible to CTLA-4/PD-1 blockade

Philipp Müller, Matthias Kreuzaler, Tarik A. Khan,

Science Translational Medicine

2015

328

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Ulrike Nitz, Oleg Gluz, Matthias Christgen,

Breast Cancer Research and Treatment

2017

183

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen,

Annals of Oncology

2017

162

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Ulrike Nitz, Oleg Gluz, Michael Clemens,

Journal of Clinical Oncology

2019

144

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor–Positive Phase II Randomized Trial—Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

Nadia Harbeck, Oleg Gluz, Matthias Christgen,

Journal of Clinical Oncology

2017

143

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

Oleg Gluz, Ulrike Nitz, Cornelia Liedtke,

JNCI Journal of the National Cancer Institute

2017

122

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

Daniel Hofmann, Ulrike Nitz, Oleg Gluz,

Trials

2013

114

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Oleg Gluz, Ulrike Nitz, Nadia Harbeck,

Annals of Oncology

2008

102

The prognostic impact of age in different molecular subtypes of breast cancer

Cornelia Liedtke, Achim Rody, Oleg Gluz,

Breast Cancer Research and Treatment

2015

99

Page 1